Tumormarker

Abkürzungen

AFP = Alpha-Fetoprotein

b2m = b2-Mikroglobulin

CA 19 - 9/50/195/242/125/72 - 4/15 - 3 = Cancer Antigen …

CA 27.29 = Cancer Antigen ...

CAM 26/29 = Cancer Associated Mucin

CEA = Carcino-Embryonales Antigen

CYFRA 21 - 1 = Cytokeratin-Fragment …

HAMA = Human Anti-Mouse (Monoclonal) Antibodies

HCG = human Chorion-Gonadotropin

HTG = Humanes Thyreoglobulin

MCA = Mammary Carcinoma Antigen

NSE = Neuronen-spezifische Enolase

PAP = prostate acid phosphatase

PLAP = plazentare alkalische Phosphatase

uPA = Urokinase-Plasminogen-Aktivator

PAI-1 = Plasminogen-Aktivator-Inhibitor

PHI = Phosphohexose-Isomerase

ProGRP = Pro-Gastrin-Releasing Peptide

PSA = Prostata-spezifisches Antigen

PTH = Parathormon

SCCA = squamous cell carcinoma antigen (neu gegenüber SCC)

TAG -12 = Tumor Associated Globulin

TK = Thymidin-Kinase

TPA = Tissue Polypeptide Antigen

TPS = Tissue Polypeptide Specific Antigen

ASCO = American Society of Clinical Oncology

AJCC = American Joint Committee on Cancer

EGTM = European Group on Tumor Markers

NACB (American) National Academy of Clinical Biochemistry

UICC = Union Internationale pour la lutte Contre le Cancer

Literatur

• 1 Duffy M J, van Dalen A, Haglund C. et al . Clinical utility of biochemical markers in colorectal cancer. European Group on Tumour Markers (EGTM) guidelines.  Eur J Cancer. 2003;  39 718-727
• 2 European Group on Tumour Markers (EGTM) . Consensus Recommendations.  Anticancer Research (http://egtm.web.med.uni-muenchen.de/). 1999;  19 2785-2820
• 3 Fleisher M, Dnistrian A M, Sturgeon C M, Lamerz R, Wittliff J L. Practice Guidelines and recommendations for use of tumor markers in the clinic. Washington, AACC Press In: Diamandis EP, Fritsch HA, Lilja H, Chan DW, Schwartz MK, editors. Tumor Markers - Physiology, pathobiology, technology and clinical applications (http://www.nacb.org/LMPG/Monograph_TumorMarkers.pdf) 2002: 33-63
• 4 Gerl A, Lamerz R, Clemm C, Mann K, Wilmanns W. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?.  Clin Cancer Res. 1996;  2 1565-1570
• 5 Hernandez J, Thompson I M. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.  Cancer. 2004;  101 894-904
• 6 International germ cell collaborative group (IGCCCG) . International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancer.  J Clin Oncol. 1997;  15 594-603
• 7 Jänicke F, Prechtl A, Thomssen C. et al. For the German Chemo No Study Group . Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.  J Natl Cancer Instit. 2001;  93 913-920
• 8 Jeffery G M, Hickey B E, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer (Cochrane Review). Issue 2 Chichester, UK: John Wiley & Sons, Ltd In: The Cochrane Library 2004
• 9 Lamerz R. AFP isoforms and their clinical significance (overview).  Anticancer Res. 1997;  17 2927-2930
• 10 Mazumdar M, Bajorin D F, Bacik J, Higgins G, Motzer R J, Bosl G J. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.  J Clin Oncol. 2001;  19 2534-2541
• 11 Reiter W, Stieber P, Krämling H J. et al . Prognostische Faktoren bei Patienten mit Magenkarzinom - eine univariate und multivariate statistische Analyse klinischer und klinisch-chemischer Daten.  J Lab med. 1996;  20 470-474
• 12 Reiter W, Stieber P, Reuter C. et al . Preoperative levels of CEA and CA 19 - 9 and their prognostic significance in colorectal carcinoma.  Anticancer Res. 1997;  17 2935-2938
• 13 Rosen M, Chan L, Ceart R W, Vukasin P, Anthone G. Follow-up of colorectal cancer: a meta-analysis.  Dis Colon Rectum. 1998;  40 1116-1126
• 14 Rustin G JS, Nelstrop A E, McClean P. et al . Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.  J Clin Oncol. 1996;  14 1545-1551
• 15 Rustin G JS, Marples M, Neltstrop A E. et al . Use of CA 125 to define progression of ovarian cancer in patients with perstistently elevated levels.  J Clin Oncol. 2001;  10 4054-4057
• 16 Schmoll H J, Souchon R, Krege S. et al . European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).  Ann Oncol. 2004;  15 1377-1399
• 17 Shimada M, Takenaka K, Fujiwara Y. et al . Des-g-carboxy prothrombin and a-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma.  Cancer. 1996;  78 2094-2100
• 18 Umehara Y, Kimura T, Yoshida M, Oba N, Harada Y. Comparison of doubling times of serum carcinoembryonic antigen produced by various metastatic lesions in recurrent gastric and colorectal carcinomas.  Cancer. 1993;  71 4055-4059
• 19 Yamaguchi K, Stieber P. Diagnosis of small cell lung cancer by ProGRP.  J Lab Med. 2003;  27 26-30
• 20 Yedema C A, Kenemans P, Voorhorst F. et al . CA 125 half-life in ovarian cancer: a multivariate survival analysis.  Br J Cancer. 1993;  67 1361-1367